Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $95.00.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...

Originally published by Gilead Sciences View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma.

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...